F3 has a worldwide, exclusive license to Amifostine-related intellectual property—patents and rights to clinical trial data—developed at the University of Chicago by the co-chair of our Scientific Advisory Board, Dr. David Grdina. We collaborate with Dr. Grdina and the university on an ongoing basis as we expand our suite of intellectual property.

At the University of Chicago, Dr. Grdina’s professional research has focused on developing new strategies to prevent therapy-induced secondary cancers in patients having a good prognosis and relatively long-life expectancy following treatment. This research on Amifostine and its treatment benefits as a cytoprotectant, spanning nearly four decades and more than 70 clinical and research trials, has led Dr. Grdina to conclude that amifostine is an effective radioprotectant against the damage caused by CT scans.

Potential partners: contact us to discuss how we might collaborate.